Abstract Objective To describe the development and implementation of an automated platform for genomic risk prediction that integrates multiple data types. Materials and methods Using the REDCap infrastructure, we constructed the R4 (Recruitment, Results, and Risk Reduction) platform to intake data from clinical sites, partner laboratories, participant surveys, and electronic health record (EHR) data across 13 institutions. Results The R4 Portal successfully integrated data to generate genome-informed risk assessments (GIRAs) across 11 conditions for a 23 840 person cohort. Testing phases and quality control led to network-wide protocols ensuring consistency and accuracy. Discussion As the science of estimating disease risk evolves, standardized and high-throughput methods of collecting and manipulating complex data are required. Platforms should be open-source, modular, and reusable, ensuring flexibility, security, and integration across healthcare environments. Conclusion The electronic MEdical Records and GEnomics (eMERGE) network successfully generated and returned comprehensive risk profiles using logic and data specific to 11 conditions in a secure and semi-automated fashion employing a customized REDCap database.
Jennifer Morse, M. He, Hana Bangash et al.· JAMIA Open· 0 citations
Rare disease diagnosis depends on expert reasoning that is scarce and difficult to transfer; off-the-shelf large language models (LLMs) rank the correct disease first in only 35.4% of benchmark cases. Here we show that this expert reasoning can be converted into a scalable AI capability through a governed learning process rather than model training alone. We developed liteOdyssey through Policy Iteration with Human Feedback (PIHF), an in-context policy-learning method adapted from generalized policy iteration in reinforcement learning, in which model failures and expert corrections consolidate into an clinician-gated policy that turns an off-the-shelf LLM into an agentic diagnostic system. We demonstrated that such a policy improved diagnostic accuracy to match the best published systems at a fraction of their deployment footprint, generalized to unseen diseases, transferred across models, and remained under clinician control. Across 1,243 public benchmark cases spanning 722 rare diseases, liteOdyssey ranked the correct disease first in 59.3% of cases versus 26.5% without the policy, with nearly identical gains on the 1,193 cases and 679 diseases excluded from policy development. Ablations showed that gains exceeded automated prompting improvement and source access alone, and the policy transferred without modification across closed- and open-weight models. In 515 Undiagnosed Diseases Network patients, liteOdyssey again improved accuracy, and blinded physicians rated its differentials more often exact and less often unhelpful. Through PIHF, expert reasoning becomes an LLM capability that experts can inspect, revise, and transfer across models.
Minh-Ha Nguyen, Erica Gray, B. Schuler et al.· 0 citations